Abstract
Sleep disorders are one of the most common non-motor symptoms in Parkinson's disease (PD). It can cause a notable decrease in quality of life and functioning in PD patients, as well as place a huge burden on both patients and caregivers. The most cited sleep disorders in PD included insomnia, restless legs syndrome (RLS), rapid eye movement (REM), sleep behavior disorders (RBD), excessive daytime sleepiness (EDS) and sleep disordered breathing (SDB), which can appear alone or several at the same time. In this review, we listed the recommended pharmacological treatments for common sleep disorders in PD, and discussed the recommended dosages, benefits and side effects of relative drugs. We also discussed non-pharmacological treatments to improve sleep quality, including sleep hygiene education, exercise, deep brain stimulation, cognitive behavior therapy and complementary therapies. We tried to find proper interventions for different types of sleep disorders in PD, while minimizing relative side effects.
Keywords: Parkinson's disease, insomnia, restless legs syndrome, RBD, excessive daytime sleepiness, sleep disordered breathing, pharmacological treatments, non-pharmacological treatments.
Graphical Abstract
Current Neuropharmacology
Title:Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease
Volume: 19 Issue: 12
Author(s): Reyisha Taximaimaiti, Xingguang Luo and Xiao-Ping Wang*
Affiliation:
- Department of Neurology, Shanghai TongRen Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336,China
Keywords: Parkinson's disease, insomnia, restless legs syndrome, RBD, excessive daytime sleepiness, sleep disordered breathing, pharmacological treatments, non-pharmacological treatments.
Abstract: Sleep disorders are one of the most common non-motor symptoms in Parkinson's disease (PD). It can cause a notable decrease in quality of life and functioning in PD patients, as well as place a huge burden on both patients and caregivers. The most cited sleep disorders in PD included insomnia, restless legs syndrome (RLS), rapid eye movement (REM), sleep behavior disorders (RBD), excessive daytime sleepiness (EDS) and sleep disordered breathing (SDB), which can appear alone or several at the same time. In this review, we listed the recommended pharmacological treatments for common sleep disorders in PD, and discussed the recommended dosages, benefits and side effects of relative drugs. We also discussed non-pharmacological treatments to improve sleep quality, including sleep hygiene education, exercise, deep brain stimulation, cognitive behavior therapy and complementary therapies. We tried to find proper interventions for different types of sleep disorders in PD, while minimizing relative side effects.
Export Options
About this article
Cite this article as:
Taximaimaiti Reyisha , Luo Xingguang and Wang Xiao-Ping *, Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease, Current Neuropharmacology 2021; 19 (12) . https://dx.doi.org/10.2174/1570159X19666210517115706
DOI https://dx.doi.org/10.2174/1570159X19666210517115706 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Tea and Health: Studies in Humans
Current Pharmaceutical Design Translocator Protein (TSPO) Role in Aging and Alzheimer’s Disease
Current Aging Science How to Measure Exercise Performance
Current Respiratory Medicine Reviews Effects of Leptin on Biliary Lipids: Potential Consequences for Gallstone Formation and Therapy in Obesity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Oxysterol Derivatives of Cholesterol in Neurodegenerative Disorders
Current Medicinal Chemistry Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment
Current Pharmaceutical Design Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Aquaporin Biology and Nervous System
Current Neuropharmacology Imaging of Pancreatic Beta-Cell Signal-Transduction
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Tyrosinase Electrochemical Biosensors Monitoring Medicinally Significant Substances
Current Medicinal Chemistry Brain Drug Delivery: Overcoming the Blood-brain Barrier to Treat Tauopathies
Current Pharmaceutical Design Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Homotrimeric dUTPases; Structural Solutions for Specific Recognition and Hydrolysis of dUTP
Current Protein & Peptide Science Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry Atopic Dermatitis and Cytokines: Recent Patents in Immunoregulatory and Therapeutic Implications of Cytokines in Atopic Dermatitis - Part I: Cytokines in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Gait-Related Strategies for the Prevention of Plantar Ulcer Development in the High Risk Foot
Current Diabetes Reviews Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design